The potassium channel blocker, dalfampridine diminishes ouabain-induced arrhythmia in isolated rat atria

References

• Aiba, T., et al., 2015. Acetylcholine Suppresses Ventricular Arrhythmias and Improves Conduction and Connexin‐43 Properties During Myocardial Ischemia in Isolated Rabbit Hearts. Journal of cardiovascular electrophysiology, 26, 678–685.
   PubMed Web of Science ®Google Scholar
• Andreasen, M., 2002. Inhibition of slow Ca(2+)-activated K(+) current by 4-aminopyridine in rat hippocampal CA1 pyramidal neurones. British journal of pharmacology, 135, 1013–1025.
   PubMed Web of Science ®Google Scholar
• Bellou, A., et al., 2016. 4-Aminopyridine, a blocker of voltage-dependent K+ channels, restores blood pressure and improves survival in the Wistar Rat Model of Anaphylactic Shock. Critical care medicine, 44, e1082–e1089.
   PubMed Web of Science ®Google Scholar
• Blight, A.R., 2011. Treatment of walking impairment in multiple sclerosis with dalfampridine. Therapeutic advances in neurological disorders, 4, 99–109.
   PubMedGoogle Scholar
• Blight, A.R., Henney, H.R., and Cohen, R., 2014. Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis. Annals of the new york academy of sciences, 1329, 33–44.
   PubMed Web of Science ®Google Scholar
• Bourque, C., 1988. Transient calcium-dependent potassium current in magnocellular neurosecretory cells of the rat supraoptic nucleus. The journal of physiology, 397, 331–347.
   PubMed Web of Science ®Google Scholar
• Chiba, S., 1976. Differences in chronotropic and inotropic responses of canine atrial muscle and SA node pacemaker activity to adenosine and ACh. Japanese heart journal, 17, 73–79.
   PubMedGoogle Scholar
• Choisy, S.C., et al., 2007. Increased susceptibility to atrial tachyarrhythmia in spontaneously hypertensive rat hearts. Hypertension, 49, 498–505.
   PubMed Web of Science ®Google Scholar
• Damsma, G., et al., 1988. Differential effects of 4-aminopyridine and 2, 4-diaminopyridine on the in vivo release of acetylcholine and dopamine in freely moving rats measured by intrastriatal dialysis. European journal of pharmacology, 145, 15–20.
   PubMed Web of Science ®Google Scholar
• Diness, J.G., et al., 2010. Inhibition of Small Conductance Ca 2+-Activated K + Channels Terminates and Protects against Atrial Fibrillation. Circulation: Arrhythmia and electrophysiology, 3, 380–390. CIRCEP. 110.957407.
   PubMed Web of Science ®Google Scholar
• Diness, J.G., et al., 2011. Effects on atrial fibrillation in aged hypertensive rats by Ca2+-activated K + channel inhibition. Hypertension, 57, 1129–1135.
   PubMed Web of Science ®Google Scholar
• Dorian, P., 2000. Mechanisms of action of class III agents and their clinical relevance. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the european society of cardiology, 1, C6–C9.
   PubMed Web of Science ®Google Scholar
• Dunn, J., and Blight, A., 2011. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. Current medical research and opinion, 27, 1415–1423.
   PubMed Web of Science ®Google Scholar
• Gerlach, U., 2003. Blockers of the slowly delayed rectifier potassium IKs channel: potential antiarrhythmic agents. Current medicinal chemistry-cardiovascular & hematological agents, 1, 243–252.
   PubMedGoogle Scholar
• Hayes, K.C., 2011. Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis. Neuropsychiatric disease and treatment, 7, 229.
   PubMed Web of Science ®Google Scholar
• Iaci, J.F., et al., 2013. Dalfampridine improves sensorimotor function in rats with chronic deficits after middle cerebral artery occlusion. Stroke, 44, 1942–1950.
   PubMed Web of Science ®Google Scholar
• Jara, M., Barker, G., and Henney, H.R., 3rd, 2013. Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US. Neuropsychiatric disease and treatment, 9, 365.
   PubMed Web of Science ®Google Scholar
• Judge, S.I., and Bever, C.T., 2006. Potassium channel blockers in multiple sclerosis: neuronal K v channels and effects of symptomatic treatment. Pharmacology & therapeutics, 111, 224–259.
   PubMed Web of Science ®Google Scholar
• Khan, R.N., et al., 1997. Ca2+ dependence and pharmacology of large-conductance K+ channels in nonlabor and labor human uterine myocytes. American journal of physiology-cell physiology, 273, C1721–C1731.
   PubMed Web of Science ®Google Scholar
• Levy, M.N., 1971. Brief reviews: sympathetic-parasympathetic interactions in the heart. Circulation research, 29, 437–445.
   PubMed Web of Science ®Google Scholar
• Littleton, J.T., and Ganetzky, B., 2000. Ion channels and synaptic organization: analysis of the Drosophila genome. Neuron, 26, 35–43.
   PubMed Web of Science ®Google Scholar
• Mathie, A., and Veale, E.L., 2007. Therapeutic potential of neuronal two-pore domain potassium-channel modulators. Current opinion in investigational drugs, 8, 555.
   PubMed Web of Science ®Google Scholar
• Moradi, S., et al., 2016. Involvement of inflammatory cytokines in antiarrhythmic effects of clofibrate in ouabain-induced arrhythmia in isolated rat atria. Advances in pharmacological sciences, 2016, 9128018.
   PubMedGoogle Scholar
• Nikoui, V., et al., 2015. Prostaglandin F 2α modulates atrial chronotropic hyporesponsiveness to cholinergic stimulation in endotoxemic rats. European journal of pharmacology, 748, 149–156.
   PubMed Web of Science ®Google Scholar
• Schmitt, N., Grunnet, M., and Olesen, S.-P., 2014. Cardiac potassium channel subtypes: new roles in repolarization and arrhythmia. Physiological reviews, 94, 609–653.
   PubMed Web of Science ®Google Scholar
• Simpson, D.M., et al., 2014. Dalfampridine in patients with chronic post-ischemic stroke deficits: results from a phase 2 study. American heart association, 45, A150.
   Google Scholar
• Singh, B.I., and Ahmed, R., 1994. Class III antiarrhythmic drugs. Current opinion in cardiology, 9, 12–22.
   PubMed Web of Science ®Google Scholar
• Skibsbye, L., et al., 2011. The duration of pacing-induced atrial fibrillation is reduced in vivo by inhibition of small conductance Ca2+-activated K+ channels. Journal of cardiovascular pharmacology, 57, 672–681.
   PubMed Web of Science ®Google Scholar